Upon completion of this activity, the participants should be able to:
- Recognize the currently approved immune checkpoint inhibitors (ICIs)-based regimens in advanced NSCLC.
- Implement effective techniques for identifying and managing immune-related adverse events (irAEs) in patients during ICI treatment and after its discontinuation.
- Consider complex cases in a multidisciplinary manner, namely with colleagues from other specialties.
- Manage the side effects of the immune-suppressive drugs given to treat irAEs.